Matches in Wikidata for { <http://www.wikidata.org/entity/Q92718636> ?p ?o ?g. }
- Q92718636 description "artículu científicu espublizáu en marzu de 2019" @default.
- Q92718636 description "scientific article published on 27 March 2019" @default.
- Q92718636 description "wetenschappelijk artikel" @default.
- Q92718636 description "наукова стаття, опублікована 27 березня 2019" @default.
- Q92718636 name "Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial" @default.
- Q92718636 name "Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial" @default.
- Q92718636 type Item @default.
- Q92718636 label "Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial" @default.
- Q92718636 label "Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial" @default.
- Q92718636 prefLabel "Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial" @default.
- Q92718636 prefLabel "Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial" @default.
- Q92718636 P1433 Q92718636-90017085-E1C7-44CC-A274-B3B0EEBDBE17 @default.
- Q92718636 P1476 Q92718636-3CB4DF94-35B6-4E08-ABF9-F21754EBA21B @default.
- Q92718636 P2093 Q92718636-005947BA-0B5A-4A93-835E-3BDDE76415F4 @default.
- Q92718636 P2093 Q92718636-2D17FDFA-9DF7-44C2-BEBC-531E7E840BE7 @default.
- Q92718636 P2093 Q92718636-93B65DB4-DEC0-477E-876F-9E8DDD5064D4 @default.
- Q92718636 P2093 Q92718636-A5FB6DE1-A981-44B3-9FD1-3DBADD5AAAB1 @default.
- Q92718636 P2093 Q92718636-C00AE13F-EDC9-4F62-9B80-91A3630F199F @default.
- Q92718636 P2093 Q92718636-E333E649-7887-498D-A2DD-94D446609950 @default.
- Q92718636 P2093 Q92718636-F0EC670E-A568-4318-99D5-C9B461997242 @default.
- Q92718636 P2860 Q92718636-000E6092-8362-4FAE-883E-2FA18D13C148 @default.
- Q92718636 P2860 Q92718636-0A0BADC7-EE09-42D6-A655-E49CFC871E2F @default.
- Q92718636 P2860 Q92718636-2E5876EB-8C59-4DEA-A0A2-9875A224EF47 @default.
- Q92718636 P2860 Q92718636-404F62D5-7F13-481B-9B52-472CB5CE83D5 @default.
- Q92718636 P2860 Q92718636-474FBEA2-BFC7-4393-8ACC-FE1FD509AFA1 @default.
- Q92718636 P2860 Q92718636-4F7C280D-DE9C-4BC5-8CB0-5719E74408AD @default.
- Q92718636 P2860 Q92718636-5793F4DD-34C8-4BAC-94CA-D26EF1B3FC32 @default.
- Q92718636 P2860 Q92718636-5A3D8E5D-5063-4CB0-BA8D-39CEBB70EAF3 @default.
- Q92718636 P2860 Q92718636-6B5F33EF-B067-4E6B-AA7C-43F215E2E902 @default.
- Q92718636 P2860 Q92718636-6D62A8C5-8165-48E3-B2F3-4331ED615EA0 @default.
- Q92718636 P2860 Q92718636-711F0C17-EA98-4F6A-AE26-4120C31840F0 @default.
- Q92718636 P2860 Q92718636-72C34AE7-12D4-46DE-8D4F-E667AE248BFE @default.
- Q92718636 P2860 Q92718636-75B68733-73F1-47DD-8904-57683FD2938A @default.
- Q92718636 P2860 Q92718636-7D76EA37-F1B2-4E9C-BD2F-24A6740FA48D @default.
- Q92718636 P2860 Q92718636-ACBA4401-49BE-4251-A1C8-BC6800A1B426 @default.
- Q92718636 P2860 Q92718636-BE509473-1A0B-4D6E-B98C-48EE7CC41AB7 @default.
- Q92718636 P2860 Q92718636-CBCA1E42-5DBB-47E2-9721-0017C30AE579 @default.
- Q92718636 P2860 Q92718636-DB0A9837-F4D5-459B-9C42-752154F6B791 @default.
- Q92718636 P2860 Q92718636-EB01FF7E-CB5F-49B7-89C8-352FD7D58B49 @default.
- Q92718636 P2860 Q92718636-ED4F2E0C-EF33-402B-B8F2-0878B801434A @default.
- Q92718636 P304 Q92718636-2B936A00-74AC-4BD6-9C8F-2AA1CF799054 @default.
- Q92718636 P31 Q92718636-B0696864-08B1-4B14-AD3F-3960781C162A @default.
- Q92718636 P356 Q92718636-0B0C148C-4220-4DCD-9E3B-1977DE1E2BC6 @default.
- Q92718636 P433 Q92718636-EE7B5095-CB5B-4B0F-81DC-F9A09BE77C02 @default.
- Q92718636 P478 Q92718636-EA431890-83EF-4AF2-A8E5-3ACD6B093304 @default.
- Q92718636 P50 Q92718636-0BA580AD-89AE-467F-A0E3-CC167428FD47 @default.
- Q92718636 P50 Q92718636-18FFF96F-D8B2-4335-AB36-7524ACA1B883 @default.
- Q92718636 P50 Q92718636-216BBEE3-710E-4B88-B91E-0093991C3434 @default.
- Q92718636 P50 Q92718636-2EF034D7-1988-4E8D-A90B-7F6159D6C9F5 @default.
- Q92718636 P50 Q92718636-3E89F5C5-D85B-4D1B-B69C-FEA95013696C @default.
- Q92718636 P50 Q92718636-4DF97A84-F934-4F6B-BB07-6941CC88A216 @default.
- Q92718636 P50 Q92718636-6826025F-6F8F-4D45-BBCF-59D89447967E @default.
- Q92718636 P50 Q92718636-77CA169E-6E9A-44EE-918A-5FCF4B7D4E8C @default.
- Q92718636 P50 Q92718636-9AF1FF70-DE4C-43FD-938A-81E324EABBA1 @default.
- Q92718636 P50 Q92718636-A993E4DD-CC52-4A2E-B8CC-969B78487830 @default.
- Q92718636 P50 Q92718636-B2B9BB79-8BCB-4B9A-BEC8-E94E8E018ED9 @default.
- Q92718636 P50 Q92718636-B5DD6CE0-B0E2-4FAD-BEB6-2B03586BD0B2 @default.
- Q92718636 P50 Q92718636-BC61FA58-BCC2-4E9F-AD4E-EEDB2C50A89A @default.
- Q92718636 P50 Q92718636-D1BAE999-3150-44A6-8894-4558E2F4CD8D @default.
- Q92718636 P50 Q92718636-E4820397-0537-45A7-A9AB-17A5803C1827 @default.
- Q92718636 P50 Q92718636-E7815384-D036-4CF5-83A5-01E4AA136951 @default.
- Q92718636 P577 Q92718636-262C6F82-D331-446A-8DEA-C887234CAA42 @default.
- Q92718636 P698 Q92718636-E0A3A7E9-49D9-4FEA-885E-BC8A19DC1CC1 @default.
- Q92718636 P921 Q92718636-42694BAA-1EFC-4673-886E-5B7C4AEDCD7D @default.
- Q92718636 P921 Q92718636-5D015260-D7F0-4159-9E34-82536C810B93 @default.
- Q92718636 P356 S1470-2045(18)30940-9 @default.
- Q92718636 P698 30928620 @default.
- Q92718636 P1433 Q13747613 @default.
- Q92718636 P1476 "Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial" @default.
- Q92718636 P2093 "Caroline Robert" @default.
- Q92718636 P2093 "James Larkin" @default.
- Q92718636 P2093 "John M Kirkwood" @default.
- Q92718636 P2093 "Kohinoor Dasgupta" @default.
- Q92718636 P2093 "Roy Koruth" @default.
- Q92718636 P2093 "Stephanie Manson" @default.
- Q92718636 P2093 "Victoria Atkinson" @default.
- Q92718636 P2860 Q27853091 @default.
- Q92718636 P2860 Q34315676 @default.
- Q92718636 P2860 Q34664981 @default.
- Q92718636 P2860 Q36471118 @default.
- Q92718636 P2860 Q37132768 @default.
- Q92718636 P2860 Q38680472 @default.
- Q92718636 P2860 Q38784111 @default.
- Q92718636 P2860 Q38802138 @default.
- Q92718636 P2860 Q38904833 @default.
- Q92718636 P2860 Q39311439 @default.
- Q92718636 P2860 Q39421413 @default.
- Q92718636 P2860 Q40182275 @default.
- Q92718636 P2860 Q40875359 @default.
- Q92718636 P2860 Q42262252 @default.
- Q92718636 P2860 Q47551890 @default.
- Q92718636 P2860 Q47824495 @default.
- Q92718636 P2860 Q48044922 @default.
- Q92718636 P2860 Q52586819 @default.
- Q92718636 P2860 Q53841735 @default.
- Q92718636 P2860 Q59586296 @default.
- Q92718636 P304 "701-710" @default.
- Q92718636 P31 Q13442814 @default.
- Q92718636 P356 "10.1016/S1470-2045(18)30940-9" @default.
- Q92718636 P433 "5" @default.